Almirall Throws Down Gauntlet To Dupixent With New Lebrikizumab Data

The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.